FDA Awards QIDP Designation for Prevention of Chlamydia to Evofem Biosciences

SAN DIEGO, Feb. 9, 2022. Evofem Biosciences, Inc., announced today that the U.S. Food and Drug Administration (FDA) has awarded " Qualified Infectious Disease Product " (QIDP) Designation to EVO100 (the investigational name for Phexxi (lactic acid,...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials